Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Targeted Therapy: Increasing Therapeutic Alternatives in Metastatic Breast Cancer

Release Date: March 27, 2009| Expiration Date: March 27, 2010
0.75 AMA PRA Category 1 Credit(s)™| Mar 5, 2009, Miami, FL

Lecture Overview

For today’s oncologists, the rapidly evolving area of targeted therapy for breast cancer leads to challenges in patient care and treatment decision making. For patients with ErbB2+ disease in the metastatic setting, disease progression following prior ErbB2-targeted therapy is common; several recent studies have addressed therapeutic options, such as utilization of small-molecule tyrosine kinase inhibitors with chemotherapy, combination regimens coupling 2 ErbB-targeted agents, or inhibitors of interrelated pathways, for this patient population. Another area of debate is treatment strategy selection for the frontline treatment of patients with ErbB2+ metastatic breast cancer. Traditionally, treatment options included an ErbB2-targeted agent with or without chemotherapy but recent studies have suggested that, for some patients, combining targeted therapy with a hormonal agent might be effective, while ongoing trials are examining the potential efficacy of all-biologic regimens combining ErbB2-directed and antiangiogenic agents. The Targeted Therapy: Increasing Therapeutic Alternatives in Metastatic Breast Cancer symposium will review and discuss the latest information on biologic therapies for ErbB2+ metastatic breast cancer. A presentation of relevant case studies and panel discussion will be used to illustrate current treatment recommendations and highlight newer therapeutic approaches as well as promote interaction and discussion about clinical issues that are still a matter of controversy.

This educational program is directed toward medical oncologists, surgeons, and radiation oncologists interested in the treatment of breast cancer. Physician assistants, research nurses, and fellows interested in the treatment of patients with breast cancer are also invited to participate.

Upon completion of this educational activity, you should be able to:

  • Evaluate the use of biologic agents, including after progression on prior ErbB2-targeted therapy and as frontline therapy, in patients with advanced/metastatic ErbB2+ breast cancer
  • Discuss the biologic rationale for and clinical efficacy and safety of combining ErbB-targeted agents with hormonal or antiangiogenic therapies for the treatment of metastatic breast cancer
  • Incorporate data from clinical trials and current treatment recommendations concerning the combination of targeted therapies for patients with metastatic breast cancer into practice in order to improve treatment decision making

Instructions for Participation

  1. Read the following information before beginning the educational activity.
  2. Complete the Pretest.
  3. View and study all Flash video presentations.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Accreditation and Credit Designation

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Complete the test(s) and evaluation by March 27, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Targeted Therapy: Increasing Therapeutic Alternatives in Metastatic Breast Cancer symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Lisa Carey, MD
Research Funding – Biogen Idec, Bristol-Myers Squibb Company, Genentech, Inc., GlaxoSmithKline; Paid Consultant/Advisory Board – Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline, Pfizer Inc., sanofi-aventis U.S., Wyeth Pharmaceuticals; Speaker’s Bureau – Pfizer Inc.

Michael Untch, MD, PhD
Speaker’s Bureau – GlaxoSmithKline, Novartis Pharma AG, Roche Pharmaceuticals

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users

If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users

Compatible Web browsers include:

Additional software requirements include:

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

©Copyright 2009 by Physicians’ Education Resource.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

All correspondence should be directed to:
Editor, Targeted Therapy: Increasing Therapeutic Alternatives in Metastatic Breast Cancer
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:


  1. GlaxoSmithKline